{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-b/diagnosis/how-to-test-for-hepatitis-b/","result":{"pageContext":{"chapter":{"id":"706362c9-e255-511b-83b4-74b853c926c7","slug":"how-to-test-for-hepatitis-b","fullItemName":"How to test for hepatitis B","depth":2,"htmlHeader":"<!-- begin field 38539748-660a-4dd9-85aa-2e2b618a3336 --><h2>How do I test for hepatitis B?</h2><!-- end field 38539748-660a-4dd9-85aa-2e2b618a3336 -->","summary":"","htmlStringContent":"<!-- begin item 81edc0f3-6c44-4baf-9a7c-310038004a64 --><!-- begin field a00db520-bc35-4b67-bc15-107743ad0155 --><ul><li><strong>Diagnosis of hepatitis B virus (HBV) is based upon the presence of serological markers (antigens and antibodies) in plasma or serum. These include:</strong><ul><li><strong>Hepatitis B Surface Antigen (HBsAg)</strong> — indicates presence of viral envelope, and suggests that the person is infectious. It rises during the incubation period, and may be cleared early in the course of the disease. It is undetectable in around 10% of people by the time the test is performed. Chronic HBV infection is indicated by the persistence of serum HBsAg for more than 6 months.</li><li><strong>Hepatitis B e antigen (HBeAg)</strong> — detectable in the serum during both the early phases of acute infection and some chronic infections. Usually associated with relatively high levels of virus replication. People with chronic HBV tend to be more infectious if HBeAg is detected.  If HBeAg has been cleared, anti-HBe is usually detected, and infectivity is lower.</li><li><strong>Antibody to HBeAg (Anti-HBe)</strong> — present following clearance of HBeAg from the plasma. Disappearance of HBeAg, development of anti-HBe, and a decline in HBV-DNA, indicate control of viral replication and predict resolution of acute hepatitis B. </li><li><strong>Antibody to HBcAg (anti-HBc)</strong> — indicates current or previous HBV infection. Appears at the onset of symptoms in acute infection and persists for life. May be absent very early in acute infection.</li><li><strong>IgM antibody to hepatitis core antigen (anti-HBc IgM)</strong> — indicates recent (within the last six months) HBV infection. Quantification may be useful to distinguish between acute and chronic infection. It is usually replaced gradually by immunoglobulin G (IgG) anti-HBc.</li><li><strong>IgG a</strong><strong>ntibody to hepatitis core antigen (a</strong><strong>nti-HBc IgG) — </strong>generally persists for life and is indicative of past infection.</li><li><strong>Antibody to HBsAg (anti-HBs)</strong> — indicates recovery from and immunity to HBV. Anti-HBs without anti-HBc is a marker of immunization.<strong> </strong>Anti-HBs is quantified to measure vaccination response.</li></ul></li><li><strong>Additional tests include quantification of HBV DNA (often referred to as HBV viral load), and HBV core avidity testing.</strong><ul><li>High levels of HBV DNA are associated with a greater risk of progression to cirrhosis and hepatocellular cancer.</li><li>Core avidity testing can differentiate between acute and chronic core IgM infection.</li></ul></li><li><strong>Use clinical judgment to determine the required tests, depending on the suspected diagnosis:</strong><ul><li>Initial testing should ideally be for (at least) HBsAg and anti-HBc.</li><li>Further tests may be required depending on the findings.</li><li>Positive HBsAg and positive anti-HBc IgM confirm an acute infection, particularly if supported by clinical suspicion and raised ALT.</li><li>Positive HBsAG and anti-HBc (total or IgG) but negative anti-HBc IgM confirm a chronic infection.</li><li>Different combinations of antibodies and antigens, alongside other findings, can indicate the <a class=\"topic-reference internal-reference\" href=\"/topics/hepatitis-b/background-information/complications-prognosis/\">phase</a> of a chronic infection.</li></ul></li><li><strong>Provide full clinical details to the laboratory </strong><strong>to allow selection of the appropriate tests, including:</strong><ul><li>The person's vaccination status.</li><li>Whether the test is for past exposure or response to vaccination.</li><li>Whether or not acute hepatitis is suspected.</li><li>Whether the person is immunocompromised (when hepatitis B virus [HBV]-DNA may be of more use).<ul><li>Note: the specific tests available may vary between laboratories.</li></ul></li></ul></li><li><p><strong>Table 1. </strong>Interpretation of serology tests for hepatitis B.</p><table><thead><tr><th colspan=\"1\"><p>Test</p></th><th colspan=\"1\"><p>Acute Hepatitis B</p></th><th colspan=\"1\"><p>Immunity following infection</p></th><th colspan=\"1\"><p>Immunity due to vaccination</p></th><th colspan=\"1\"><p>Chronic Hepatitis B <strong>— Active</strong></p></th><th colspan=\"1\"><p>Chronic Hepatitis B <strong>— Inactive Carrier</strong></p></th></tr></thead><tbody><tr><td colspan=\"1\">HBsAg</td><td colspan=\"1\">+</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td><td colspan=\"1\">+</td><td colspan=\"1\">+</td></tr><tr><td colspan=\"1\">Anti-HBs</td><td colspan=\"1\">–</td><td colspan=\"1\">+</td><td colspan=\"1\">+</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td></tr><tr><td colspan=\"1\">HBeAg</td><td colspan=\"1\">+</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td><td colspan=\"1\">+/–</td><td colspan=\"1\">–</td></tr><tr><td colspan=\"1\">Anti-HBe</td><td colspan=\"1\">–</td><td colspan=\"1\">+/–</td><td colspan=\"1\">–</td><td colspan=\"1\">+/–</td><td colspan=\"1\">+</td></tr><tr><td colspan=\"1\">Anti-HBc</td><td colspan=\"1\">+</td><td colspan=\"1\">+</td><td colspan=\"1\">–</td><td colspan=\"1\">+</td><td colspan=\"1\">+</td></tr><tr><td colspan=\"1\">IgM anti-HBc</td><td colspan=\"1\">+</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td></tr><tr><td colspan=\"1\">HBV DNA</td><td colspan=\"1\">+</td><td colspan=\"1\">–</td><td colspan=\"1\">–</td><td colspan=\"1\">+</td><td colspan=\"1\">+ (low)</td></tr><tr><td colspan=\"1\">ALT</td><td colspan=\"1\">Elevated</td><td colspan=\"1\">Normal</td><td colspan=\"1\">Normal</td><td colspan=\"1\">Elevated</td><td colspan=\"1\">Normal</td></tr><tr><td colspan=\"6\">Abbreviations: ALT, alanine transaminase; HBc, hepatitis B core; HBe, hepatitis B early; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IgM, immunoglobulin M.</td></tr><tr><td colspan=\"6\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">James-Koziel and Thio, 2009</a>]</td></tr></tbody></table></li></ul><!-- end field a00db520-bc35-4b67-bc15-107743ad0155 --><!-- end item 81edc0f3-6c44-4baf-9a7c-310038004a64 -->","topic":{"id":"f75dcfde-3cb4-5059-94df-19d53a6c28e9","topicId":"4fc86266-0752-4667-994f-7f6fc7e46056","topicName":"Hepatitis B","slug":"hepatitis-b","lastRevised":"Last revised in November 2019","chapters":[{"id":"986057cd-07a1-565e-9c7a-d3b3dc88368d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2331f5c5-fb51-54d1-b722-946b4f34a693","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"653459fe-510a-5a1a-92dc-8197c598c85e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"12e8fb8c-9424-5f20-90e5-65e823f603c3","slug":"changes","fullItemName":"Changes"},{"id":"2299e2ba-3fb3-5f37-9c6b-63ec8dbbffd6","slug":"update","fullItemName":"Update"}]},{"id":"c14d3383-629b-5bd6-b6c0-318bbcf86fb2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"58e5cd67-9ca7-5bfe-b2b6-bf4372ac895f","slug":"goals","fullItemName":"Goals"},{"id":"a1abbdfd-238b-55b7-8de2-09fd4ff6065b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fc44420e-13ab-526e-a0c7-ef2f93cce77b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b59d4642-5914-585b-82b1-6f7989cef100","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"af246587-2615-513e-aafc-3ea762d8aab7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bba17b9f-47f8-52cf-a8e7-111c1a5094a2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c6fa000-50a2-5823-9acb-0bd808dc51e6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dfcb6ed4-783a-5fbc-9259-096762bb7c69","slug":"definition","fullItemName":"Definition"},{"id":"e06f78dc-080c-542f-b450-356db08c00a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0c1d15cf-36ee-5c84-ad7c-e06836a161c0","slug":"transmission","fullItemName":"Transmission"},{"id":"939f1d6a-6b15-5c4f-91c8-9164e800cd87","slug":"people-at-high-risk-of-hepatitis-b","fullItemName":"People at high risk of hepatitis B"},{"id":"d452f04a-7d9d-5739-9cb9-f583eb136f3a","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"b3642d36-7175-548b-b6f0-d694e7397bd3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6acbd5e1-b0e6-527b-bad0-42c21a928d1e","slug":"when-to-test-for-hepatitis-b","fullItemName":"When to test for hepatitis B"},{"id":"706362c9-e255-511b-83b4-74b853c926c7","slug":"how-to-test-for-hepatitis-b","fullItemName":"How to test for hepatitis B"},{"id":"c0c1ae56-2316-56eb-ad65-4b85e982fc11","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"41c2681f-bf40-5b08-a518-32f2ab1206fb","fullItemName":"Management","slug":"management","subChapters":[{"id":"b2d949a2-a42f-5c0a-a955-414bac741bd3","slug":"prevention-of-infection-with-hepatitis-b","fullItemName":"Scenario: Prevention of infection with Hepatitis B"},{"id":"00ed825c-5927-50f5-940d-94d6b4001150","slug":"managing-hepatitis-b-infection","fullItemName":"Scenario: Managing hepatitis B infection"}]},{"id":"c7941282-a3b2-5716-b0cc-80cb243a7405","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8df28bde-0bc5-533e-a54b-507fd3ceee61","slug":"hepatitis-b-vaccine","fullItemName":"Hepatitis B vaccine"},{"id":"c7099851-c102-56f2-b063-021f3d00b880","slug":"analgesics","fullItemName":"Analgesics"},{"id":"6a9675fd-5496-5ca4-9a76-36ee6cc93a25","slug":"anti-emetics","fullItemName":"Anti-emetics"},{"id":"1576eb24-e96c-50e6-9976-05164be1127e","slug":"anti-pruritics","fullItemName":"Anti-pruritics"}]},{"id":"3c7651c1-b246-51db-85b3-e1b6713a47bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"548463b9-9c49-5154-bad9-fe10668804da","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8b3032fc-e20a-509b-b390-81cef2509ded","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5e0cdb38-e518-5a0c-9215-493c78f74377","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3e63144c-a0f3-5eb1-980d-a219e8a53633","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"94d851c4-3314-5a3d-801a-0a208e287514","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4df2edc1-d17c-57d1-a914-4100299c8f7d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cecf6c0b-d134-54cb-abef-c2ccab9effb6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b3642d36-7175-548b-b6f0-d694e7397bd3","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"66217fba-8a26-5f8c-b525-872a04a0f580","slug":"basis-for-recommendation-27d","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 67e0a9e1-ba0a-4877-9613-3b4727b45173 --><h3>Basis for recommendation</h3><!-- end field 67e0a9e1-ba0a-4877-9613-3b4727b45173 -->","summary":null,"htmlStringContent":"<!-- begin item 27d1cba4-584b-4fc5-a2b0-0900757b974b --><!-- begin field d1d0db74-cdc3-4e3c-9b1d-bf885b55d93a --><p>The information on hepatitis B serology is based on expert opinion within the British Liver Trust guideline <em>Hepatitis B infection and immunisation in primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">British Liver Trust, 2017</a>], the British Association of Sexual Health and HIV (BASHH) <em>2017 interim update of the 2015 BASHH National Guidelines for the Management of the Viral Hepatitides </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">BASHH, 2017</a>], the Public Health England (PHE) publication <em>Immunisation against infectious diseases</em> (the 'Green Book'), chapter 18, <em>Hepatitis B  </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2017</a>]<em>, </em>the BMJ Best Practice guideline <em>Hepatitis B</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">BMJ Best Practice, 2018</a>], the Public Health England <em>Interim guidance on the public health management and control of acute hepatitis B</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2019a</a>],  and are also consistent with the opinions of previous expert reviewers of this CKS topic.</p><h4>Providing full clinical information to the laboratory</h4><ul><li>Request for a 'hepatitis B screen' will often result in only the hepatitis B surface antigen (HBsAg) test being done. Several previous expert reviewers of this CKS topic noted that testing for both HBsAg and antibody to hepatitis B core antigen (anti-HBc) is preferable, and that detailed clinical information is essential to assist laboratories to check for the most appropriate serological markers. Expert opinion within the National Institute of Health and Care Excellence (NICE) guideline <em>Hepatitis B (chronic): diagnosis and management </em>recommends that all people who test positive for HBsAg in primary care should also be tested for HBeAg anti-HBe, anti-HBc lgM, and have their HBV DNA quantified [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">NICE, 2017</a>]. </li></ul><!-- end field d1d0db74-cdc3-4e3c-9b1d-bf885b55d93a --><!-- end item 27d1cba4-584b-4fc5-a2b0-0900757b974b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}